Parexel Closes The Acquisition Of Clinphone


PAREXEL International Corporation (NASDAQ: PRXL), a global biopharmaceutical services organization, today announced the successful closing of the acquisition of ClinPhone plc, a clinical technology organization.


Combined Capabilities Create the Industry's Largest eClinical Technology

BOSTON, MA, August 14, 2008 – PAREXEL International Corporation (NASDAQ:
PRXL), a leading global biopharmaceutical services organization, today
announced the successful closing of the acquisition of ClinPhone plc, a
leading clinical technology organization. By combining ClinPhone with
Perceptive Informatics, PAREXEL's wholly-owned technology subsidiary,
Perceptive is now one of the industry's largest eClinical technology
providers. The combined company offers unprecedented access to eClinical
technologies and resources, providing clients and service providers with the
benefits of an extensive line of products and services throughout the entire
clinical development lifecycle.

Josef von Rickenbach, Chairman and Chief Executive Officer of PAREXEL
International, said: "Biopharmaceutical companies require robust technology
solutions to increase the efficiency and productivity of clinical research.
This is especially important given the growing complexity and global nature
of clinical studies today. We believe this acquisition further solidifies
PAREXEL's leadership in providing integrated clinical and technology
expertise. Combining the sophisticated, in-depth capabilities of Perceptive
and ClinPhone represents a major step forward for PAREXEL in meeting
increased industry demand for a truly comprehensive eClinical platform.”

Steve Kent, former Chief Executive Officer of ClinPhone and newly-appointed
President of Perceptive Informatics said: "Both companies bring tremendous
capabilities to this deal. As a combined clinical technology company,
Perceptive Informatics enables customers to benefit from the efficiency of
best-inclass software and services from one source. Through the acquisition,
Perceptive has a deeper level of resources as well as a broader range of
technical and clinical expertise to drive greater innovation and meet the
industry's evolving needs.”

As a result of the transaction, Perceptive Informatics' comprehensive,
industry-leading eClinical technology offering now includes:
•ClinPhone Interactive Voice and Web Response Systems (IVRS/IWRS),
•Perceptive Medical Imaging,
•DataLabs, an Electronic Data Capture (EDC) and clinical data management
•Clinical Trial Management Systems (CTMS):
o IMPACT® enterprise CTMS solution
o TrialWorks® CTMS solution for small and mid-size companies, and
•Electronic Patient Reported Outcomes (ePRO).

Through the acquisition, Perceptive Informatics will further expand its
technology integration and implementation services. These services help
biopharmaceutical companies implement clinical trial process improvements,
extend existing applications, and enable knowledge sharing across multiple

PAREXEL plans to issue updated forward-looking financial guidance for the
first quarter of Fiscal Year 2009 and for Fiscal Year 2009 in its entirety,
through a press release to be issued after the close of the market on
September 8, 2008. The Company plans to host a conference call to discuss
the acquisition and the forward-looking guidance at 10:00 a.m. EDT on
September 9, 2008.

About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical
services organization, providing a broad range of knowledge-based contract
research, medical communications and consulting services to the worldwide
pharmaceutical, biotechnology and medical device industries. Committed to
providing solutions that expedite time-to-market and peak-market
penetration, PAREXEL has developed significant expertise across the
development and commercialization continuum, from drug development and
regulatory consulting to clinical pharmacology, clinical trials management,
medical education and reimbursement. Perceptive Informatics, Inc., a
subsidiary of PAREXEL, provides advanced technology solutions, including
medical imaging, to facilitate the clinical development process.
Headquartered near Boston, Massachusetts, PAREXEL operates in 69 locations
throughout 52 countries around the world, and has more than 8,800 employees.
For more information about PAREXEL International visit

This release contains "forward-looking" statements regarding future results
and events. For this purpose, any statements contained herein that are not
statements of historical fact may be deemed forward-looking statements.
Without limiting the foregoing, the words "believes,” "anticipates,”
"plans,” "expects,” "intends,” "appears,” "estimates,” "projects,”
"targets,” and similar expressions are also intended to identify
forward-looking statements. The forward-looking statements in this release
involve a number of risks and uncertainties. The Company's actual future
results may differ significantly from the results discussed in the
forward-looking statements contained in this release. Important factors that
might cause such a difference include, but are not limited to, risks
associated with: actual operating performance; actual expense savings and
other operating improvements resulting from recent restructurings; the loss,
modification, or delay of contracts which would, among other things,
adversely impact the Company's recognition of revenue included in backlog;
the Company's dependence on certain industries and clients; the Company's
ability to win new business, manage growth and costs, and attract and retain
employees; the Company's ability to complete additional acquisitions and to
integrate newly acquired businesses or enter into new lines of business,
including, but not limited to, the successful business integration and
anticipated synergy achievements in connection with the ClinPhone
acquisition; the impact on the Company's business of government regulation
of the drug, medical device and biotechnology industry; consolidation within
the pharmaceutical industry and competition within the biopharmaceutical
services industry; the potential for significant liability to clients and
third parties; the potential adverse impact of health care reform; and the
effects of exchange rate fluctuations and other international economic,
political, and other risks. Such factors and others are discussed more fully
in the section entitled "Risk Factors" of the Company's Quarterly Report on
Form 10-Q for the period ended March 31, 2008 as filed with the SEC on May
9, 2008, which "Risk Factors” discussion is incorporated by reference in
this press release. The forward-looking statements included in this press
release represent the Company's estimates as of the date of this release.
The Company specifically disclaims any obligation to update these
forward-looking statements in the future. These forward-looking statements
should not be relied upon as representing the Company's estimates or views
as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation,
Perceptive Informatics is a trademark of Perceptive Informatics, Inc., and
ClinPhone is a registered trademark of ClinPhone Limited. All other names or
marks may be registered trademarks or trademarks of their respective
business and are hereby acknowledged.

Related Videos
Greg Ball, Founder, ASAP Process Consulting image credit screen shot from video
Janice Chang, CEO, TransCelerate BioPharma @ video screenshot.
Applied Clinical Trials and LabConnect
Related Content
© 2024 MJH Life Sciences

All rights reserved.